Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.50 |
| ▸ | HTR2A | P28223 | 11/20 | 0.50 |
| ▸ | DRD3 | P35462 | 11/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468939 | 0.94 | DRD2 (0.52) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL12468861 | 0.78 | HTR2C (0.58) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL12468950 | 0.78 | ALDH1A1 (0.44) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL12468829 | 0.75 | HRH3 (0.62) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL11835040 | 0.75 | DRD2 (0.61) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL3679735 | 0.74 | HTR2C (0.69) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL15348174 | 0.74 | DRD2 (0.52) | DRD2HTR2ADRD3HTR2C | |
| Hydrochloric Acid SCHEMBL11830632 | 0.74 | DRD2 (0.60) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL15348353 | 0.72 | HTR7 (0.48) | DRD2HTR2A | |
| SCHEMBL12469400 | 0.71 | ALDH1A1 (0.44) | DRD2HTR2ADRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | claimed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | claimed |
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | DRD2 2163/4885HTR2A 52/4885DRD3 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.